Cam­brex com­pletes $24M API man­u­fac­tur­ing fa­cil­i­ty; Twist and LakePhar­ma part­ner on an­ti­body con­tract work

Cam­brex Cor­po­ra­tion $CBM com­plet­ed its $24 mil­lion API (HPA­PI) man­u­fac­tur­ing fa­cil­i­ty at its site in Charles City, IA. The fa­cil­i­ty is un­der­go­ing val­i­da­tion and is ex­pect­ed to be ready to start cus­tomer projects in May.

PDL Bio­Phar­ma is in­vest­ing up to $60 mil­lion in­to Evofem Bio­sciences. PDL is in­vest­ing along­side two ex­ist­ing Evofem share­hold­ers, which have the right to in­vest up to $10 mil­lion each. The mon­ey will be used to back their pre-com­mer­cial ac­tiv­i­ties for Am­pho­ra, its con­tra­cep­tive gel for women.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.